Cite
HARVARD Citation
Patt, Y. et al. (n.d.). INST OX‐05‐024: first line gemcitabine, oxaliplatin, and erlotinib for primary hepatocellular carcinoma and bile duct cancers: a multicenter Phase II trial. Cancer medicine. pp. 2042-2051. [Online].